secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001549595-25-000067
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay
--------------------------------------------------------------------------------

- All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).
- Ratification of PricewaterhouseCoopers as independent auditor for FY2025 approved (64,950,599 for, 85,040 against).
- Non-binding advisory vote on named executive officer compensation passed (49,788,975 for, 11,341,365 against).
- Annual meeting held May 19, 2025; 65,056,197 shares (85.33% of voting power) constituted a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/0001549595-25-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/nrix-20250519.htm
  HTML page:      https://secwatch.observer/filing/0001549595-25-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer